No person knows for sure what the future will hold for stocks in the new year. However, it can be fun to attempt to predict what might happen.
Three Fool.com contributors have done just that. Here’s why they think that Axsome Therapeutics (NASDAQ: AXSM), Novo Nordisk (NYSE: NVO), and Vertex Pharmaceuticals (NASDAQ: VRTX) will soar in 2024.
A potential breakout year for this biotech
Prosper Junior Bakiny (Axsome Therapeutics): The past two years have been transformative for Axsome Therapeutics. The company finally became a commercial-stage biotech by marketing two therapies, from which it is generating some sales. That was an important milestone, but Axsome’s revenue remains modest while it is still chronically unprofitable.
The biotech failed to keep up with the broader market in 2023, but 2024 could be very different. Axsome’s late-stage pipeline includes several programs that could…
